News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Akorn, Inc. Announces FDA Approval of Ciprofloxacin HCl Ophthalmic Solution USP, 0.3%
December 12, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced that the U.S. Food and Drug Administration has granted approval for Akorn’s Abbreviated New Drug Application (ANDA) for Ciprofloxacin HCl Ophthalmic Solution USP, 0.3%.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
·
4 min read
·
Annalee Armstrong
Regulatory
‘All Wrapper, No Gift’: FDA Releases New Rare Disease Approval Framework
September 4, 2025
·
2 min read
·
Tristan Manalac
Vaccines
Prasad Signals Steeper Requirements for COVID-19 Vaccines
September 3, 2025
·
3 min read
·
Tristan Manalac
FDA
Offit Out at FDA Vaccine Advisory Committee After HHS Rebuff
September 2, 2025
·
3 min read
·
Heather McKenzie